Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...

Worried about mental health effects of ozempic? Here's what recent studies reveal about safety concerns and what you should discuss with your doctor ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

The female hormone estrogen appears to promote binge drinking in women, a new mouse study published recently in the journal ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...

Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday. The drug will likely dominate ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...